SERUM LEVELS OF OMENTIN-1 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER: THE IZMIR ONCOLOGY GROUP (IZOG) STUDY

YASAR YILDIZ¹, YUKSEL KUCUKZEYBEK¹, AHMET ALACACIOGLU¹, HALIL TASKAYNATAN¹, IBRAHIM YILDIZ2, UMUT VAROL¹, LEYLA DEMIR³, MURAT AKYOL¹, TARIK SALMAN¹, UTKU OFLAZOGLU¹, TOYGAR KALKAN¹, MUSTAFA OKTAY TARHAN⁴

¹Clinics of Medical Oncology, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey - ²Clinics of Medical Oncology, Acıbadem University Atakent Hospital, Istanbul, Turkey - ³Clinics of Biochemistry, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir, Turkey - ⁴Institute of Oncology, University of Dokuz Eylül, Izmir-Turkey

Background: The role of molecular markers in ovarian cancer is still a matter of debate. This study was conducted to determi- ne the clinical significance of serum Omentin-1 in epithelial ovarian cancer (EOC) patients in the current matched case-control study.

Material and methods: Fourty-one patients with advanced EOC and 41 healthy people were included in the study. Serum Omentin values were measured by quantitative ELISA method.

Results: The median serum Omentin-1 values was 46.6 pg/ml in patients and this was significantly higher than healthy con- trols (median 35.5) (p=0.045). There was positive correlation between serum omentin and serum CA-125 levels (r = 0.34, p =0.028). We found no relationship between serum Omentin-1 levels and any prognostic parameters analyzed, including age of the patients, histology, tumor grade, stage of the disease, debulking surgery and response to chemotherapy. Survival analysis did not show statisti- cally significant effect of serum Omentin-1 level on overall survival (p = 0.91)

Conclusions: These results indicated that serum Omentin-1 values were significantly elevated in patients with advanced ove- rian carcinoma compared to healthy people. Further studies with a greater number of patients are required to confirm the importan- ce of serum Omentin-1 levels in ovarian cancer.